Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Novo Nordisk stock sinks on weight loss drug trial letdown
In This Article:
Novo Nordisk (NVO) shares stumble after the results of the drugmaker's weight loss drug trial showed that patients using the drug dropped only around 15% of their weight, compared to the 25% that was expected by the company and investors.
Madison Mills and Brad Smith outline the details on Morning Brief.
To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.
This post was written by Naomi Buchanan.
Related Videos
Terms and Privacy Policy